GeneDx, a genetic testing and analytics developer, announced this week that it is collaborating with Epic to expand access to its rapid whole genome sequencing services. The focus is specifically on neonatal intensive care units, the company says. By integrating with the Epic electronic health record, GeneDx aims to connect directly with health systems, helping clinicians more easily receive orders and send results.
Patients can now have rWGS data more seamlessly integrated into their longitudinal medical record, helping providers deliver more personalized treatment plans. GeneDx says it's working to broaden the availability of exome and genome testing across patient populations. With regard to neonatal patients, it is participating in , a study at the University of Washington designed to assess how easy access to routine rWGS can improve care for critically ill infants at Seattle Children's Hospital.
And through its support of the – Genomic Uniform-screening Against Rare Diseases In All Newborns – GeneDx is working to improve understanding of genomic screening for healthy newborns not currently included in standard newborn screening. The company notes that wider adoption of standard WGS at birth can speed time to diagnosis and help prevent or slow progression of rare disease in pediatric patients. GeneDx says it has seen significant growth in its rapid testing business, with more and more payers appreciative of rWGS.
The company notes that 11 states now offer Medicaid co.
